We are offering a research position for a highly motivated Postdoc to study the epigenetic differences in neuroblastoma. Neuroblastoma is a pediatric tumor with often a fatal outcome. Primary tumors go in complete remission upon therapy, but relapse as resistant disease. At the department of Oncogenomics we study relapse mechanisms by high throughput-, bioinformatic- and cell biology- technologies. We found that neuroblastoma consist of two phenotypically divergent types of tumor cells (van Groningen et al., Nature Genetics 2017). They share the same genetic defects and can transdifferentiate into one another. They also have highly divergent epigenetic landscapes, including different super enhancers and core regulatory circuitries. One of the cell types is more therapy-resistant and may cause relapses. In this project funded by the Netherlands Cancer Foundation, we will clarify the epigenetic mechanisms underlying the trans-differentiation between the two cell types and their deregulation in cancer. You will apply screening technologies with in vitro trans-differentiation models, chromatin analyses and protein-protein interactions of chromatin modifiers and collaborate with the bioinformatics team in the for bioinformatic analyses. Effects of drugs intervening with epigenetic modification will be tested.
Continuation of a research line funded by the Netherlands Cancer Foundation.
Analyze high-throughput data including RNA-seq, ChIP-seq and whole genome sequencing and extract new ideas.
Set up the protocol and analysis for proteomics related to epigenetic modifiers.
Select and screen epigenetic inhibitors and test in a model system.
We are looking for an ambitious postdoc with an interest in epigenetic regulation.
You have obtained a PhD in molecular or cancer biology.
You are analytical and creative.
Experience in molecular biology, cell culture and protein-protein interaction techniques is required.
Experience with analysis of high-throughput data (e.g. expression arrays, RNA-seq and ChIP-seq) is an advantage, but we are supported by a strong bioinformatics team (head Dr. Jan Koster)
Good communication skills in English is required.
The department of Oncogenomics has a long-standing research line in neuroblastoma and collected extensive high throughput data on tumors and cell lines. Research teams focus on cellular re-programming, epigenetics, drug-resistance and bioinformatics. The epigenetic differences between the two neuroblastoma cell phenotypes is the focus of the group of Dr. Linda Valentijn. You will work in this team to study the function of epigenetic modifiers in cellular transition. Combination of hands on research and bioinformatics in the R2 platform (http://r2.amc.nl) allows integration and analysis of data of neuroblastoma and other tissues.
We look forward to receive your motivation letter and CV!
Preferred start date for this position is as soon as possible.
For more information about this position, you can contact Dr. Linda J. Valentijn, via firstname.lastname@example.org
For more information about the application procedure please contact Tanja Hart, Recruitment Adviser, via T: 06-21603178 or E: email@example.com
A reference check, screening and hiring test may be part of the procedure. Read hier whether this also applies to you.
Acquisition in response to this vacancy is not appreciated.